Kossel × Biomnipotent: Deepening the Peripheral Vascular Intervention Industry Ecosystem and Practicing the Path of Long-Term Commitment with Perseverance

The history of the global medical device industry demonstrates that mergers and acquisitions (M&A) are an inevitable path for the growth of industry giants. International enterprises, represented by Medtronic, have continuously consolidated their market advantages and secured positions in high-growth sectors through strategic M&A. Today, China's medical device industry has officially entered the second half of its development, characterized by integration and collaboration.

Recently, Kossel Medtech (Suzhou) Co., Ltd. (hereinafter referred to as "Kossel"), a platform-based enterprise in the field of Chinese vascular interventional devices, completed the strategic acquisition of the peripheral vascular interventional diagnosis and treatment business of Shanghai Biomnipotent Medical Technology Co., Ltd. (hereinafter referred to as "Biomnipotent"). This acquisition further enhances Kossel's one-stop diagnostic and therapeutic system in the field of peripheral intervention, also marking that Chinese peripheral intervention companies are advancing through licensing deals, transitioning from a technology follower to an ecosystem builder, and charging towards the global high ground.

The medical device industry is characterized by long value chains and numerous segments. The sector has now entered a new development phase marked by "oversupply," with dozens to even hundreds of companies clustered in each niche segment, and core technological capabilities dispersed across various market participants. Consequently, competition and challenges in the second half of the industry's development cycle are becoming more complex and severe. Platform-based enterprises capable of spanning the entire value chain, integrating upstream and downstream resources, and ultimately achieving global development have become scarce resources in the market.

In this context, unlike the licensing deal model for innovative drugs, which relies on "blockbuster products," the core of medical device licensing deals lies in building a complete closed loop of clinical value — equipping surgical solutions with a comprehensive toolchain, particularly in highly procedural specialized fields such as vascular interventional diagnosis and treatment.

Licensing deal capabilities have become a key indicator for assessing the strategic vitality and long-term potential of vascular intervention companies. They serve as a critical link enabling enterprises to transition from internal value creation to external value realization, and represent a historic opportunity for China's medical device industry to secure global positioning, integrate resources, address weaknesses, and accelerate innovation. According to the "China Healthcare Industry White Paper 2025," the scale of mergers and acquisitions in China's healthcare industry reached RMB 75 billion in 2024, a significant year-on-year increase of 82%, far exceeding the global average annual growth rate of 6%-10%.

It is worth emphasizing that companies should not chase trends or engage in mergers and acquisitions (M&A) for the sake of M&A itself. The core value of licensing deals lies in strengthening and completing portfolios; this requires not only precise timing of M&A activities but also effective post-merger asset integration. All strategic layouts must ultimately return to the fundamental clinical needs and benefit the broad patient population.

Kossel's strategic acquisition of Biomnipotent represents a concrete implementation of the closed-loop clinical value logic — achieving not only an ecological restructuring of resources in the peripheral intervention field, but also creating a more comprehensive and high-quality integrated diagnostic and therapeutic solution for physicians and patients.

Compared with coronary interventions, peripheral vascular interventions, despite having a similarly high incidence rate, involve a wider variety of blood vessels, greater anatomical variability, and more diverse procedural techniques. No single product or technology can cover the entire diagnosis and treatment process. Furthermore, peripheral vascular diseases are characterized by complex disease courses and insidious early symptoms. These factors have led to an overall low penetration rate in the treatment of peripheral vascular diseases, with significant clinical unmet needs in both peripheral arterial and venous diseases. Meanwhile, as global population aging continues to intensify and the patient base expands, the peripheral intervention market possesses significant growth potential. According to Frost & Sullivan data, China's peripheral intervention industry is still in its early stages of development, with the market size expected to exceed RMB 30 billion by 2030, maintaining a compound annual growth rate (CAGR) of approximately 20%.

Market Size of Peripheral Vascular Intervention, 2015–2030E (Source: Frost & Sullivan)

In the peripheral interventional diagnosis and treatment sector, where the market ceiling for individual products is low but the potential for comprehensive solutions is vast, enterprises can only achieve long-term development through strategic cooperation, mergers and acquisitions, resource integration, and ecosystem building, thereby delivering superior product portfolios and more efficient diagnostic and therapeutic solutions to clinical practice.

The competitive logic of peripheral vascular interventions is undergoing a fundamental shift: the metric for clinical value has moved from the performance parameters of individual products to the ability to provide a complete "diagnosis–decision–treatment" closed loop for complex procedures.

Kossel's growth trajectory precisely mirrors this industry trend. In 2013, it strategically entered the market through the therapeutic segment, establishing advantages in the treatment of venous diseases, arteriovenous thrombus removal, and vascular preparation with its product portfolio, including the Octoparms® Vena Cava Filter, K-Rhino™ Thrombus Aspiration System, and Tanghulu® Balloon. The core purpose of this acquisition of Biomnipotent is precisely to strengthen the key diagnostic segment of "intravascular imaging."

Biomnipotent's independently developed K-VisionMax™ Jingbao™ Disposable Peripheral Ultrasound Diagnostic Catheter and Intravascular Ultrasound Diagnostic Equipment are at the leading level in China, capable of real-time 3D imaging of the vascular lumen, vessel wall, and surrounding structures. The system demonstrates significant advantages in key performance parameters, clinical applicability, supply chain stability, and cost control, effectively enhancing the precision of intraoperative decision-making and improving long-term patient outcomes. The deep integration of diagnostic and therapeutic toolchains will further accelerate the implementation of Kossel's integrated precision diagnosis and treatment solutions.

K-VisionMax™ Jingbao™ Disposable Peripheral Ultrasound Diagnostic Catheter and Intravascular Ultrasound Diagnostic Device

Currently, value creation in the medical device industry is rapidly evolving from single products to "comprehensive clinical solutions." In addition to VisionMax™ Jingbao™, Biomnipotent has made deep strategic investments in both active and passive diagnostic and therapeutic products. Its independently developed ultrasonic vibration guidewire can efficiently recanalize chronic total occlusions (CTO) in coronary and peripheral arteries. The company's ultrasound therapy system for varicose veins targets a ten-billion-RMB niche market, offering patients a new non-invasive treatment option. Furthermore, the company possesses a portfolio of other innovative active devices, including combination ultrasound thrombolysis systems and vascular interventional surgical robots.

The aforementioned products are highly complementary to and deeply integrated with Kossel's existing peripheral interventional diagnosis and treatment product line, jointly establishing an integrated interventional solution that covers the full lifecycle of peripheral arterial and venous diseases.

This M&A embodies the ideal convergence of timing, location, and human harmony, laying a solid foundation for synergistic development between both parties. In terms of timing, the peripheral intravascular ultrasound sector has not yet entered a stage of intense competition, leaving ample room for market expansion. Currently, the VisionMax™ Jingbao™ disposable peripheral ultrasound diagnostic catheter has obtained a Class III medical device registration certificate, while the intravascular ultrasound diagnostic equipment is in the process of certification, poised for a concentrated release of market value. At this juncture, completing the merger and acquisition can maximize value creation. In terms of team synergy, Biomnipotent initially considered an independent development path. However, in light of industry trends and changes in the external environment, the team has chosen to embrace a larger platform, moving forward together with an open and pragmatic approach to uphold their original entrepreneurial vision and contribute to the overall progress of the industry.

The synergy among these three elements not only ensures the steady and long-term success of both companies in the high-growth peripheral intervention sector, but also, by leveraging the integration of core teams and the resonance of shared development philosophies, achieves genuine collaborative innovation and ecosystem integration, thereby maximizing the long-term value of M&A integration for corporate growth and industrial upgrading.

By extending the time horizon and broadening the industry perspective, it becomes evident that this acquisition is not an isolated case but another critical validation of Kossel's dual-wheel drive strategy of "independent innovation + ecosystem integration." This path of ecosystem integration, underpinned by long-termism, was foreshadowed as early as the initial stages of the company's development.

Reviewing Kossel's thirteen-year development journey, its growth trajectory is clearly discernible: from early single-point innovative breakthroughs focused on vena cava filters to the systematic construction of a platform-based layout across four major segments — peripheral interventions, electrophysiology, coronary interventions, and core raw materials; from completing its first overseas acquisition — the acquisition of Irish company Micell, achieving global evidence generation and commercialization layout, up to this integration of Biomnipotent through domestic ecosystem integration, enhancing the precision diagnostic capabilities of the peripheral interventional platform.

Kossel's Integrated Layout: "Peripheral + Coronary + Electrophysiology + Core Raw Materials"

Currently, centralized volume-based procurement has become the new normal in the industry, with market competition returning to its fundamental focus on value. Leveraging robust technological innovation, reliable product quality, and extensive clinical application experience, Kossel has had multiple products selected for national and local volume-based procurement programs at reasonable prices. In early 2026, Kossel officially announced a deep strategic partnership with Medtronic. Amidst the global wave of mergers and acquisitions, Kossel is pioneering a path of industrial upgrading that is patient-centric, focused on comprehensive solutions, and driven by long-term collaborative synergy.

Regarding this collaboration, Kossel stated that the acquisition of Biomnipotent is a key step for Kossel to perfect its one-stop diagnostic and therapeutic system for peripheral interventions. By deeply integrating Biomnipotent's technological advantages in intravascular imaging with Kossel's existing product portfolio for venous and arterial diseases, Kossel has established a comprehensive solution covering the entire lifecycle of peripheral vascular diseases. In the future, Kossel will continue to adhere to its dual-drive strategy of "independent innovation + ecosystem integration," leveraging long-term strategic commitment to propel China's peripheral intervention industry toward the high end of the global value chain.

Biomnipotent stated that this collaboration with Kossel represents a significant opportunity for both parties to leverage their complementary strengths and achieve synergistic development. Biomnipotent's expertise in precision diagnostics will be deeply integrated into Kossel's integrated ecosystem, leveraging its platform resources and innovation system to further advance the field of peripheral interventional diagnostics. Biomnipotent will work hand in hand with Kossel to provide more comprehensive and precise solutions for clinical practice, jointly contributing to the upgrading and development of China's vascular intervention industry.

No M&A, No Giants. Yet more critical than the deals themselves is clarifying the original intent behind mergers and acquisitions and defining the path to integration — a truth amply validated by the century-long M&A history of multinational giants. Looking ahead to the next phase, Kossel will consistently uphold its corporate culture of "pragmatism, efficiency, collaboration, sharing, perseverance, and dedication," leveraging systematic management mechanisms to accelerate the incubation of innovative products, continuously unlock innovation value, and provide comprehensive solutions for clinical practice. Meanwhile, building on its solid foundation of innovation and robust ecosystem integration capabilities, Kossel is steadily advancing toward its goal of becoming a leading enterprise in the vascular intervention sector.